Monte Rosa Therapeutics (GLUE) News Today $6.93 +2.12 (+44.07%) Closing price 04:00 PM EasternExtended Trading$6.59 -0.34 (-4.85%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Monte Rosa Therapeutics Up Today?Toggle Visibility of Why Is Monte Rosa Therapeutics Up Today?Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) shares climbed today after the company announced a second collaboration with Novartis to discover and develop molecular glue degraders for immune-mediated diseases. Investors are reacting to the deal’s financial terms, strategic implications and potential to accelerate Monte Rosa’s immunology pipeline. Positive Sentiment: Receives a $120 million upfront payment from Novartis, significantly extending Monte Rosa’s cash runway to advance its preclinical and clinical programs. Monte Rosa stock soars after $120M Novartis collaboration deal Positive Sentiment: Eligible for up to $5.7 billion in total deal value—including option exercises, milestone payments and tiered royalties—if programs reach development and sales milestones. Novartis returns to Monte Rosa for second time in a year with $5.7bn deal Positive Sentiment: This is Monte Rosa’s second agreement with Novartis following the October 2024 VAV1 degrader license, deepening a high-value partnership with a global immunology leader. Monte Rosa & Novartis Partner to Develop Immune-Mediated Disease Treatments Positive Sentiment: Stock reaction has been strong, with shares surging in premarket and midday trading on optimism around the collaboration’s revenue potential. Monte Rosa Therapeutics Shares Soar on Drug Partnership with Novartis Neutral Sentiment: Novartis receives an exclusive license to an undisclosed discovery target plus options to license two additional preclinical immunology programs. Monte Rosa Therapeutics Announces Collaboration with Novartis Neutral Sentiment: Collaboration leverages Monte Rosa’s AI/ML-enabled QuEEN™ platform to identify and optimize molecular glue degraders against challenging immune targets. Novartis dives deeper into protein degraders with second Monte Rosa deal Neutral Sentiment: Focus is on historically undruggable immune-mediated disease targets, reflecting a high-risk, high-reward strategy typical of molecular glue platforms. Novartis assembles 2nd molecular glue deal with Monte Rosa Posted 2h agoAI Generated. May Contain Errors. GLUE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Monte Rosa stock rises after pact with NovartisSeptember 15 at 2:33 PM | msn.comNovartis returns to Monte Rosa for second time in a year with $5.7bn dealSeptember 15 at 2:33 PM | finance.yahoo.comMonte Rosa stock soars after $120M Novartis collaboration dealSeptember 15 at 9:32 AM | ca.investing.comMonte Rosa Therapeutics Shares Soar on Drug Partnership with NovartisSeptember 15 at 9:32 AM | marketwatch.comNovartis signs up to $5.7 billion licensing deal with Monte Rosa TherapeuticsSeptember 15 at 9:32 AM | msn.comMonte Rosa surges premarket on Novartis collaboration dealSeptember 15 at 9:32 AM | finance.yahoo.comMonte Rosa Therapeutics jumps in premarket on Novartis collaborationSeptember 15 at 9:32 AM | msn.comNovartis Secures Exclusive License and Collaboration Agreement with Monte Rosa Therapeutics for Immunology Drug DevelopmentSeptember 15 at 7:30 AM | quiverquant.comQMonte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated DiseasesSeptember 15 at 7:00 AM | globenewswire.comParkwood LLC Buys 385,000 Shares of Monte Rosa Therapeutics, Inc. $GLUESeptember 8, 2025 | marketbeat.comNuveen LLC Acquires Shares of 117,672 Monte Rosa Therapeutics, Inc. $GLUESeptember 7, 2025 | marketbeat.comBVF Inc. IL Purchases 2,895,661 Shares of Monte Rosa Therapeutics, Inc. $GLUESeptember 5, 2025 | marketbeat.comAlphaQuest LLC Cuts Holdings in Monte Rosa Therapeutics, Inc. $GLUESeptember 3, 2025 | marketbeat.comMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2025 | globenewswire.comMonte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business UpdatesAugust 7, 2025 | globenewswire.comMonte Rosa Therapeutics (GLUE) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comReadystate Asset Management LP Acquires Shares of 287,000 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)July 23, 2025 | marketbeat.comMonte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditionsJuly 22, 2025 | msn.comMonte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesJuly 21, 2025 | globenewswire.comMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.3% - Should You Buy?July 17, 2025 | marketbeat.comMonte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader MedicinesJuly 3, 2025 | globenewswire.comMonte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesJune 10, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Two Sigma Investments LPJune 2, 2025 | marketbeat.comMonte Rosa Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comVestal Point Capital LP Sells 505,000 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 21, 2025 | marketbeat.comSuvretta Capital Management LLC Sells 1,095,202 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 19, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New $644,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 18, 2025 | marketbeat.comParkwood LLC Sells 103,620 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 16, 2025 | marketbeat.comAnalysts Set Expectations for GLUE Q4 EarningsMay 14, 2025 | marketbeat.comMonte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comBVF Inc. IL Invests $19.19 Million in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 6, 2025 | marketbeat.comMonte Rosa Therapeutics (GLUE) Expected to Announce Earnings on ThursdayMay 3, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Increases Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)May 2, 2025 | marketbeat.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast CancerApril 28, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Marshall Wace LLPApril 28, 2025 | marketbeat.comAvoro Capital Advisors LLC Has $30.15 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 23, 2025 | marketbeat.comJump Financial LLC Buys Shares of 154,842 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 23, 2025 | marketbeat.comMonte Rosa Therapeutics Insider Ups Holding During YearApril 22, 2025 | finance.yahoo.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Down 23.0% in MarchApril 21, 2025 | marketbeat.comVanguard Group Inc. Buys 622,134 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 17, 2025 | marketbeat.comNorges Bank Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)April 13, 2025 | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Drops By 12.6%April 3, 2025 | marketbeat.comVersant Venture Management LLC Purchases New Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)March 27, 2025 | marketbeat.comInsider Buying: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Buys 10,000 Shares of StockMarch 26, 2025 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Acquires $58,400.00 in StockMarch 26, 2025 | insidertrades.comMonte Rosa Therapeutics: Exercise Extreme CautionMarch 25, 2025 | seekingalpha.comFY2029 Earnings Estimate for GLUE Issued By WedbushMarch 24, 2025 | marketbeat.comMonte Rosa Therapeutics price target raised to $17 from $15 at WedbushMarch 23, 2025 | markets.businessinsider.comMonte Rosa Therapeutics price target lowered to $10 from $11 at Wells FargoMarch 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.com Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLUE Media Mentions By Week GLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼1.860.94▲Average Medical News Sentiment GLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼102▲GLUE Articles Average Week Get the Latest News and Ratings for GLUE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies GPCR News TRVI News ELVN News TLRY News LENZ News NUVB News WVE News MAZE News AMLX News ORIC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLUE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLUE Stock Alerts